 |
Orrin Devinsky is Professor of Neurology, Neurosurgery, and Psychiatry at NYU School of Medicine. He directs the NYU and Mount Sinai Comprehensive Epilepsy Centers, the Staten Island University Hospital Comprehensive Epilepsy Center, and the Saint Barnabas Institute of Neurology and Neurosurgery (INN). He received his B.S. and M.S. from Yale University, M.D. from Harvard Medical School and interned at Boston’s Beth Israel Hospital. He completed neurology training at the New York Hospital-Cornell Medical Center and his epilepsy fellowship at the NIH.
His epilepsy research interests include: quality-of-life, cognitive and behavioral issues in epilepsy, surgical therapy, and new medications. He has published widely in epilepsy and behavioral neurology, with more than 200 articles and chapters and more than 15 books. He has chaired several committees of the American Epilepsy Society and has served as a Board member. He is active on the national boards of both the American Academy of Neurology and the Epilepsy Foundation. He is the Co-Editor of epilepsy.com, Epilepsy and Behavior, and Reviews in Neurological Diseases. Furthermore he is on the Editorial Board of several journals, and serves as a reviewer for many journals. |
 |
Jacqueline French, MD has focused her research efforts on development of new therapeutics for epilepsy. She has written many articles, editorials and chapters and has edited two books on this subject, and is the co-director of a bi-annual symposium on trial design and its implications. This symposium is an opportunity for representatives from government (the FDA and the NIH), members of the academic community, and members of the private research community to discuss drug development and determine new strategies. This meeting has led to the implementation of new trial designs, as well as new strategies for the approval of drugs for use in monotherapy. Dr. French has also been active in creating practice parameters, serving on committees of the American Academy of Neurology and the American Epilepsy Society and chairing several practice parameter Task Forces. Recently, she chaired an AAN/AES committee that produced two widely quoted guidelines on the use of new antiepileptic drugs. She has also organized a multicenter effort to prospectively evaluate outcome for patients initiated on new antiepileptic drugs. She has served as an ad hoc reviewer for many journals, is an editor for Epileptic Disorders, and is the Epilepsy Section Editor of Clinical Neuropharmacology. She has served on the board of the American Epilepsy Society and the American Society of Experimental Therapeutics. In addition, she is the head of the scientific advisory board of the Epilepsy Therapy Project, a private group devoted to the development of new epilepsy therapies. She is the current director of the epilepsy course for the American Academy of Neurology. She lectures in the US and internationally on topics related to antiepileptic drug therapeutics. |
 |
Cynthia L. Harden, MD is an associate professor of neurology and neuroscience at the Weill Medical College of Cornell University in New York City. Affiliated with the Comprehensive Epilepsy Center at this institution for 12 years, Dr Harden is also an associate attending in neurology.
Dr Harden has lectured and conducted continuing medical education courses on a diverse list of epilepsy-related issues—including women’s and children’s concerns, the uses of new antiepileptic drugs, the effect of newer antiseizure treatments on sexual function, and new avenues for treating brain disease—to such groups as the American Academy of Neurology, the American Psychiatric Association, and the New York Academy of Medicine. A member of several professional societies, including the American Epilepsy Society and the American Academy of Neurology, Dr Harden serves as an officer in the epilepsy section of the Academy and is a member of its Therapeutics and Technology Assessment Subcommittee. Dr Harden’s research interests include assessing the effects of hormonal changes on epilepsy. For instance, in a study where Andrew Herzog, MD, MSc, is principal investigator, which is supported by the National Institute of Neurological Disorders and Stroke, she is exploring the effect of progesterone treatment versus placebo in women with epilepsy. Under a similar grant, Dr Harden was principal investigator in another study where she assessed hormone replacement therapy in menopausal women. Her privately funded research includes investigating the effects of add-on anastrozole in men with epilepsy. Dr Harden has also examined mood and anxiety disorders in people with epilepsy in response to various treatments and psychogenic pseudoseizures.
Dr Harden is an ad hoc reviewer for Neurology and Epilepsy Research, among other journals. She has also authored or collaborated on nearly a score of book chapters and more than 35 articles for peer-reviewed journals, such as Epilepsia, Pediatric Neurology, the Journal of Epilepsy, and the Journal of Neuroscience.
After earning her medical degree at the University of Wisconsin Medical School in Madison, Dr Harden served her internship and a year’s residency in internal medicine at St. Luke’s Hospital in New York City. She stayed in New York City to complete her residency training in neurology at Mount Sinai Hospital and a fellowship in clinical neurophysiology at Albert Einstein College of Medicine. |
 |
Dr. Gregory Krauss has been a faculty member of the Department of Neurology since July 1991. He is Associate Professor of Neurology with specialization in the evaluation and treatment of seizures and epilepsy.
Dr. Krauss' clinical practice expertise includes treating medically-resistant epilepsy, evaluating patients with unexplained seizure-like episodes, treating seizures associated with tumor and systemic illnesses, and family planning counseling for patients with epilepsy. Dr. Krauss evaluates patients who have failed standard medical therapies for possible treatment with epilepsy surgery, investigational medications, or with vagal nerve stimulation.
Current areas of research include risks for driving with epilepsy, effectiveness and safety of new and investigational seizure medications, and epilepsy surgery techniques and outcome. |
 |
Steven Schachter, MD is Editor-in-Chief of epilepsy.com and a member of the ETDP Executive Board, Board of Directors and Scientific Advisory Board. Dr. Schachter is Professor of Neurology, Harvard Medical School; Director of Research Beth Israel Deaconess Medical Center Department of Neurology; Founding Editor and Editor-in-Chief, Epilepsy & Behavior, and a member of the Board of Directors of the Epilepsy Foundation. |
